Navigation Links
Combination therapy boosts effectiveness of telomere-directed cancer cell death

Sometimes a potential target for a drug seems very promising on paper; things are often very different in reality. Its the case of telomerase inhibitors to treat cancer; they are supposed to strip the "immortal" (able to divide indefinitely) aspect of cancer cells. Yet, something in the cell seems to block their function, preventing them to inhibit completely the telomerase. What to do then? Scrap the project? Look for something else? Hell no! Look out for whats stopping the drug! Perseverance is sometimes worth it, as we can see. A new research study published in the January issue of Cancer Cell provides exciting new information about how to boost the effectiveness of a promising cancer treatment that targets telomeres in an attempt to interfere with the ability of a cancer cell to continuously divide.

Telomeres are DNA sequences found at the ends of chromosomes that play a key role in controlling the life span of cells. With every cell division, telomeres get a bit shorter until eventually they become so short that the enzymes that copy DNA for cell division no longer work properly and the cell stops dividing. In a sense, telomeres function as a kind of counting mechanism that regulates how many times a cell can divide. In contrast to normal cells, cancer cells divide continuously and uncontrollably. Scientists know that cancer cells produce an enzyme, called telomerase, which prevents telomeres from getting too short so cells can keep dividing. Telomerase is not used by healthy cells, and has been identified as a logical target for anticancer therapeutics. However, recent studies indicate that for this therapy to be effective, telomeres must be in a critically short state, requiring an extended treatment duration that can lead to drug resistance and other problems. Dr. Hiroyuki Seimiya from the Japanese Foundation for Cancer Research in Tokyo and colleagues examined what happens to cancer cells when telomerase inhib ition is combined with inhibition of an enzyme called tankyrase 1 that is involved in making telomeres accessible to telomerase. The researchers found that both tankyrase 1 activity and telomere shortening decrease the effects of telomerase inhibitors. Importantly, tankyrase inhibition enhanced telomere shortening upon treatment with a telomerase inhibitor and accelerated cancer cell death. "This study provides insight into strategies for telomere-based molecular cancer therapeutics. We expect that inhibition of tankyrase 1 will compensate for incomplete inhibition of telomerase. Consequently, this strategy would shorten the time period of drug treatment that is required for the onset of telomere crisis and reduce the potential risk of acquired drug resistance, " writes Dr. Seimiya. Hiroyuki Seimiya, Yukiko Muramatsu, Tomokazu Ohishi, and Takashi Tsuruo: "Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics".
'"/>

Source:Eurekalert


Related biology news :

1. Combination therapy leads to partial recovery from spinal cord injury in rats
2. Combination therapy improves AIDS-related lymphoma outcome
3. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
4. Combination therapy shows promising results in patients with advanced lung cancer
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... --  Avanade is helping Williams Martini Racing, one ... exploit biometric data in order to critically analyse every ... edge against their rivals after their impressive, record-breaking pit ... worked with Williams during the 2016 season to capture ... breathing rate, temperature and peak acceleration) for key members ...
(Date:12/6/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... of €500.0 million principal amount of its 1.414% senior unsecured ... 2.425% senior unsecured notes due 2026. The ... 2016, subject to the satisfaction of customary closing conditions.  The ... The Company intends to use the net ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
(Date:12/7/2016)...  Genprex, Inc. a biopharmaceutical company focused on ... announced that it has retained ICR Healthcare, a ... and advisory firm, to develop and implement an ... investor relations, public relations and digital communications to ... Genprex and its lead candidate Oncoprex, which is ...
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In a recent ... team of scientists in Guangzhou, China ... of NR2F6 in patients with early cervical cancer correlates with ... cancer tissue as well as in the normal tissue surrounding ... study and the first that I am aware of that ...
Breaking Biology Technology: